
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc is advancing its gene therapy, cellular regeneration, and precision medicine platforms, with promising initial data from its Phase 1b study of TN-201, indicating positive trends in clinical parameters and cardiac biomarkers. The company reported fourth-quarter earnings per share (EPS) of ($0.28) for 2024, which aligns closely with estimates and demonstrates tighter financial performance relative to previous expectations. Additionally, the potential for TN-201 in addressing MYBPC3-associated hypertrophic cardiomyopathy (HCM) and the management of liver enzyme elevations suggest a favorable environment for future product development and market positioning.
Bears say
Tenaya Therapeutics Inc faces a negative outlook primarily due to potential delays in transitioning its preclinical assets to clinical trials, which could weaken market sentiment and necessitate downward revisions to financial estimates. Additionally, the complexity and novelty of AAV-based gene therapy products pose significant risks related to manufacturing capacity, potentially leading to further setbacks in product development and commercialization. Compounded by the possibility of failed clinical trials and reliance on dilutive capital raises to secure funding, these fundamental challenges create uncertainties that may materially constrain Tenaya’s financial forecasts.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares